UBS Global Healthcare Conference - BILLIONTOONE INC

Based on the transcript provided, here are the extracted forward-looking statements and financial outlooks:

• Explicit Guidance:

  • Revenue Growth Rates:
    • Prenatal business: Projected ~20% annual growth through 2027 (excluding potential guideline changes or health system expansions).
    • Oncology business: Expects >100% year-over-year growth in test volumes, with acceleration expected through the second half of 2027.
  • ASP & Coverage Impact:
    • Anticipates a >100% increase in the Clinical Laboratory Fee Schedule (CLFS) for single-gene NIPT effective January 1, 2027 (TAMA in place).
    • Projects that long-term insurance coverage implementation could drive a 20% increase in total company revenue and convert to 20% profit margins.
  • Cost of Goods Sold (COGS) & Margins:
    • Target gross margins: 75% for Prenatal and ~45% for Oncology (current blended: 71%).
    • Anticipates potential short-term blended gross margin dips (1–2 percentage points) if Oncology scales faster than projected, viewed positively as a sign of volume growth.
    • MRD (Clear) Timeline: Expects the MRD business to reach gross margin breakeven within the first year of launch, avoiding negative profitability due to COGS structure.
  • Investment Efficiency (OpEx):
    • All capital and operational investments are targeted to generate 5-to-1 or 10-to-1 ROI.
    • Will not accept accounts with negative margins if ROI targets are not met, prioritizing long-term profitability over rapid volume acquisition in loss-making segments.

• Business-Segment Outlook:

  • Unity (Prenatal):
    • Geography/Customer Focus: Shifting focus to capture health systems (the remaining value/opportunity) beyond single-specialty clinics.
    • Product Expansion: Launching larger carrier screening panels and fetal risk screening panels to support genetic counselors and complete the portfolio for health system adoption.
    • Workflow Advantage: Leveraging single-gene NIPT as a "game changer" for Maternal Fetal Medicine (MFM) specialists to drive full account capture.
  • Northstar (Oncology):
    • Clear (MRD): Scheduled commercial launch on December 15. Differentiated as a tissue-free solution targeting community oncology settings (80% of future MRD utilization) where tumor-informed logistics fail.
    • Select & Response: Expecting synergies where "Response" (monitoring) acts as a wedge to drive "Select" (therapy selection) adoption and repeat testing.
    • Origin (Tissue of Origin): Expanding utility to address the 10–15% of cases with uncertain diagnoses in community settings (vs. 3% in academic settings).
  • Revenue Mix Shift: By late 2027, oncology revenue contribution and sequential growth are expected to significantly outpace prenatal, making the growth story "oncology-oriented."

• Market and Competitive Outlook:

  • Competitive Positioning:
    • Tumor-Informed MRD: Anticipated to become "commoditized" and highly competitive as tumor-informed approaches face logistical ceilings in non-colorectal cancers.
    • Differentiation: Billion to One aims to be the only solution offering tissue-free testing with sensitivity on par or superior to tumor-informed competitors.
    • Adoption Strategy: Relying on head-to-head clinical studies and physician "user-to-user" referrals rather than just peer-reviewed publications alone.
  • Market Expansion:
    • Early Detection: Positioning the technology to solve the "noise" problem in early detection, viewing tissue-free MRD and early detection as technically equivalent problems where solving one de-risks the other.
    • Community Oncology: Targeting the 80% of MRD utilization occurring in community settings where turnaround time and tissue logistics prevent adoption of current gold standards.

• Macro / Industry Outlook:

  • Regulatory/Guideline Changes:
    • Monitoring TAMA (Technical Advisory Manual for Assay Modifications and Additions) implementation scheduled for January 1, 2027, which is expected to materially improve reimbursement schedules for single-gene NIPT.
  • Reimbursement Trends:
    • Acknowledges current insurance coverage gaps for single-gene NIPT but argues that the test's low cost and self-pay accessibility minimize barriers; coverage is expected to drive long-term margin expansion.
  • Clinical Validation:
    • Emphasizes the need for prospective multi-site intended-use studies (already published for Unity) to overcome evidence and access hurdles in single-gene screening.

• Strategic Initiatives:

  • Product Launches:
    • Clear (MRD): Launching December 15 (tissue-free MRD).
    • Unity Fetal Risk Screen: Expanded portfolio with larger panels to include fetal risk screening with cell-free DNA for the baby.
  • Geographic/Service Expansion:
    • Opening new local service centers only when ROI targets (5-to-1 or 10-to-1) are met to access new accounts.
  • Public Company Operations:
    • Continued investment in back-office functions (accounting, finance, audit) to support public company status (IPO).
  • R&D Focus:
    • Heavy investment in oncology clinical studies to validate the "tissue-free" platform for early detection and MRD.

• Risks and Headwinds to Outlook:

  • Reimbursement Uncertainty: Current lack of insurance coverage limits short-term ASP lifts, though long-term impact is projected positively.
  • Logistical Barriers: Potential for slower adoption if community oncologists cannot manage the logistics of tissue-informed competitors, though Billion to One's solution mitigates this.
  • Margin Volatility: Short-term blended gross margin compression is a risk if Oncology scales faster than Prenatal, though management views this as a positive signal of growth volume.
  • Clinical Validation Timeline: Acceptance of the MRD platform requires time; "winners are not necessarily the first to market" but those who can sustain investment while proving clinical outcomes.
  • Adoption Friction: Physicians may require "research pilots" and head-to-head evidence before switching from established tumor-informed standards.

• Management Tone on the Future:

  • Confidence Level: Highly confident in the QCT technology platform's ability to reduce noise and solve "impossible" detection problems (single-gene, early cancer, tissue-free MRD).
  • Strategic Discipline: Adopting a "long-term perspective" over short-term volume; willing to walk away from accounts that do not meet strict ROI criteria.
  • Growth vs. Profitability: Emphasizes a strategy of combining "rapid growth" with "endurance" (profitability), distinguishing from competitors who may sacrifice margins for scale.
  • Market Perception: Believes the investment community currently underestimates the company's ability to grow rapidly and maintain profitability simultaneously in the MRD and early detection markets.

• Miscellaneous:

  • Financial Metrics Reference:
    • Q3 Revenue Growth: Prenatal +42%, Oncology +$17.1M (96% YoY).
    • Q3 Margins: Prenatal 71%, Blended 71%.
    • Q3 OpEx Growth: +56% (attributed to public company readiness and R&D).
  • Technology Differentiator: The "QCT backbone" allows for single-molecule level sensing, removing the sensitivity/specificity trade-off common in other ctDNA approaches.